Metabolic (dysfunction)-associated fatty liver disease (MAFLD) affects up to a third of the
global population; its burden has grown in parallel with rising rates of type 2 diabetes …

Background Although non-alcoholic fatty liver disease (NAFLD) is commonly associated
with obesity, it is increasingly being identified in non-obese individuals. We aimed to …

Nonalcoholic fatty liver disease (NAFLD) is common and partially heritable and has no
effective treatments. We carried out a genome-wide association study (GWAS) meta …

Fatty liver associated with metabolic dysfunction is common, affects a quarter of the
population, and has no approved drug therapy. Although pharmacotherapies are in …

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver diseases in high-
income countries and the burden of NAFLD is increasing at an alarming rate. The risk of …

Non-alcoholic fatty liver disease (NAFLD) is now recognised as the most common liver
disease worldwide. It encompasses a broad spectrum of conditions, from simple steatosis …

Conclusions This study demonstrates that E. multilocularis can induce T‐cell exhaustion
through inhibitory receptor TIGIT, and that blocking this checkpoint may reverse the …

Nonalcoholic fatty liver disease (NAFLD) affects around a quarter of the global population,
paralleling worldwide increases in obesity and metabolic syndrome. NAFLD arises in the …

Background and Aims Animal models of human disease are a key component of
translational hepatology research, yet there is no consensus on which model is optimal for …

When type III interferon (IFN-λ; also known as interleukin-28 [IL-28] and IL-29) was
discovered in 2003, its antiviral function was expected to be analogous to that of type I IFNs …